Immunocore Holdings (IMCR) Receivables - Other (2019 - 2023)

Immunocore Holdings (IMCR) has reported Receivables - Other for 5 consecutive years, with $6.9 million the latest figure, recorded in Q2 2023.

• Quarterly Receivables - Other changed N/A year-over-year to $6.9 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $6.9 million (changed N/A YoY) and the FY2022 annual result came in at $9.0 million, up 345.5% from the prior year.
• Receivables - Other slipped to $6.9 million in Q2 2023 per IMCR's latest filing, from $9.0 million in the prior quarter.
• Over the last five years, Receivables - Other for IMCR reached as high as $9.0 million in Q4 2022 and fell as low as $2.0 million in Q4 2021.
• A 5-year average of $5.4 million and a median of $5.8 million in 2019 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2020 — Receivables - Other plunged 51.77% — and 2022, when it soared 354.71%.
• Year by year, Receivables - Other stood at $4.7 million in 2019, then tumbled by 51.77% to $2.3 million in 2020, then fell by 12.85% to $2.0 million in 2021, then surged by 354.71% to $9.0 million in 2022, then fell by 23.27% to $6.9 million in 2023.
• According to Business Quant data, Receivables - Other over the past three periods registered $6.9 million, $9.0 million, and $7.3 million for Q2 2023, Q4 2022, and Q3 2022 respectively.